Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
125 pending office actions • 58 clients • 115 examiners • 61 art units • 0 of 125 (0%) have an AI response strategy ready
PABST PATENT GROUP LLP specializes in Biotechnology & Pharmaceuticals, where it has managed 3812 career applications. The firm has a resolved allowance rate pct of 76.2. Its prosecution history shows an avg office actions per allowance of 4.67. Currently, the firm is handling 104 pending office actions.
The 104 pending office actions represent the firm's current workload compared to its 3812 career applications. A 76.2 resolved allowance rate pct indicates the firm's historical success in obtaining grants. The avg office actions per allowance of 4.67 shows the typical number of examiner interactions required for an allowance. These figures, specifically the 76.2 resolved allowance rate pct and 4.67 avg office actions per allowance, highlight the firm's prosecution results and procedural style in the life sciences sector.
Based on the USPTO statutory response window for each pending office action. 42 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 42 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 17 (14%) |
| §103 only | 30 (24%) |
| §112 only | 10 (8%) |
| Double-patenting only | 2 (2%) |
| Double-patenting + other | 14 (11%) |
| Multi-statute (no §101) | 51 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, ANOOP KUMAR | 3 | 43.1% | +67.6% |
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.4% |
| DONOHUE, SEAN R | 2 | 41.4% | +21.0% |
| MATALKAH, FATIMAH KHALAF | 2 | 54.8% | +28.6% |
| MIKNIS, ZACHARY J | 2 | 68.6% | +32.2% |
| SVEIVEN, MICHAEL CAMERON | 2 | 37.5% | +47.9% |
| GIAMMONA, FRANCESCA FILIPPA | 2 | 37.0% | +57.7% |
| STEINKE, SEAN JAMES | 2 | 12.5% | +42.9% |
| WANG, RUIXUE | 2 | 57.4% | +17.8% |
| BALAJ, ANTHONY MICHAEL | 1 | 31.2% | +29.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | SVEIVEN, MICHAEL CAMERON | 80d overdue |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | WANG, RUIXUE | 31d overdue |
| 17641516 | NANOPARTICLES FOR SELECTIVE TISSUE OR CELLULAR UPTAKE | LAZARO, DOMINIC | 30d overdue |
| 18269114 | A METHOD | WOLLSCHLAGER, JEFFREY MICHAEL | 11d overdue |
| 18490443 | USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING | PHILIPOSE, HANNAH SARAH | 2d overdue |
| 18000425 | SSTR-2 Binding Chimeric Antigen Receptors | DRISCOLL, MAUREEN VARINA | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | SVEIVEN, MICHAEL CAMERON | 80d overdue |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | WANG, RUIXUE | 31d overdue |
| 17259766 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE | SINGH, ANOOP KUMAR | 8d overdue |
| 18248285 | METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS | GIAMMONA, FRANCESCA FILIPPA | 14d |
| 17517039 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | DONOHUE, SEAN R | 15d |
| 18179069 | ENTERAL CARBON MONOXIDE FOR THE PREVENTION AND TREATMENT OF OCULAR DISEASES | STEINKE, SEAN JAMES | 34d |
| 18178282 | PIG XENOTRANSPLANTS INTO HUMANS WITHOUT CHRONIC IMMUNOSUPPRESSION | SINGH, ANOOP KUMAR | 63d |
| Art Unit | Apps |
|---|---|
| 1653 | 5 |
| 1619 | 4 |
| 1631 | 4 |
| 1638 | 3 |
| 1625 | 3 |
| 1678 | 3 |
| 1618 | 3 |
| 1635 | 3 |
| 1658 | 3 |
| 1677 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19314645 | SYSTEM AND METHOD FOR ALGORITHMIC DIAGNOSTICS FOR EFFICIENT PRESCRIPTION OF TREATMENTS FOR B-SNIP PSYCHOSIS BIOTYPES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | BALAJ, ANTHONY MICHAEL | 3682 | §101§103 | Non-Final OA | — | Pending | Aug 29, 2025 |
| 19103225 | METHOD FOR GENERATING CELLS OF THE T CELL LINEAGE WITH ENGINEERING BROADLY REACTIVE HUMAN NOTCH LIGAND | H. Lee Moffitt Cancer Center and Research Institute, Inc. | O'NEILL, MARISOL ANN | §103§112 | Non-Final OA | — | Pending | Feb 11, 2025 | |
| 19023761 | HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF | Yale University | MAEWALL, SNIGDHA | DP | Non-Final OA | — | Pending | Jan 16, 2025 | |
| 18990391 | NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | SONG, JIANFENG | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2024 | |
| 18990707 | METHODS TO IDENTIFY A PRESENCE OR ABSENCE OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS | Powell Mansfield, Inc. | PREMRAJ, CATHERINE C | §101 | Non-Final OA | — | Pending | Dec 20, 2024 | |
| 18905699 | SHAPEABLE SCAFFOLD MATERIAL AND USES THEREOF | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) | LIU, TRACY | §103§112DP | Non-Final OA | — | Pending | Oct 03, 2024 | |
| 18849428 | BIODEGRADABLE CONTROLLED RELEASE ANTIVIRAL AGENT IMPLANTS | Yale University | BURKE, MATTHEW RYAN | §103 | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18800902 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | Research Institute AT Nationwide Children’S Hospital | SABOKTAKIN, MARJAN | 3797 | §103 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18835557 | COMPOSITIONS | Imperial College Innovations Ltd. | WRIGHT, ERIC BRANDON | §101§102§112 | Non-Final OA | — | Pending | Aug 02, 2024 | |
| 18789224 | COMPOSITION COMPRISING A CROSS-LINKED POLYOL | Volumina Medical SA | AZPURU, CARLOS A | DP | Non-Final OA | — | Pending | Jul 30, 2024 | |
| 18833322 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | PIPIC, ALMA | 1617 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18779564 | TREATMENT OF INCLUSION BODY MYOSITIS WITH ADIPOSE-DERIVED REGENERATIVE CELLS | UNIVERSITY OF KANSAS | MELLER, MICHAEL V | §102§103 | Non-Final OA | — | Pending | Jul 22, 2024 | |
| 18770447 | TREATMENT OF INCLUSION BODY MYOSITIS WITH PHENYLBUTYRATE AND MONITORING OF TREATMENT | UNIVERSITY OF KANSAS | BARSKY, JARED | §103 | Non-Final OA | — | Pending | Jul 11, 2024 | |
| 18718628 | CONCENTRATED PREMIX FOR A PLANT-BASED FROZEN CONFECTION | Magnum Icc US, LLC | WATTS, JENNA A | 1791 | §103 | Final Rejection | — | Pending | Jun 11, 2024 |
| 18661820 | BACTERIOPHAGE-DERIVED NANOPORE SENSORS | Oxford Nanopore Technologies PLC | BALL, JOHN C | 1795 | §103 | Final Rejection | 46d overdue | Pending | May 13, 2024 |
| 18653590 | OCULAR ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | The University of Hong Kong | IANNUZO, NATALIE NMN | 1653 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18653847 | ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18703995 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. | MOSHER, ERIC PARKER | §103§112DP | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18692729 | NANOPARTICLE SURFACE TOPOGRAPHY MODIFIED WITH BOTTLEBRUSH BLOCK COPOLYMERS | Yale University | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18600046 | MODIFIED O-METHYLTRANSFERASES USEFUL FOR PRODUCTION OF O-METHYLATED PHENOLIC NATURAL PRODUCTS | The University of Hong Kong | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690230 | IODIDE NANOPARTICLES AND COMPOSITIONS OF METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill | DONOHUE, SEAN R | §102§103Other | Non-Final OA | — | Pending | Mar 07, 2024 | |
| 18690140 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | D&D Pharmatech Inc. | NIEBAUER, RONALD T | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | Centre For Virology, Vaccinology And Therapeutics Limited | MATALKAH, FATIMAH KHALAF | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 | |
| 18686711 | GLP-1R AGONISTS FOR USE IN A TREATMENT OF NEUROLOGIAL IMPAIRMENT ASSOCIATED WITH VIRAL INFECTION | Neuraly, Inc. | MIKNIS, ZACHARY J | §102§103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 | |
| 18441806 | ENGINEERED GUIDE RNA SCAFFOLDS AND METHODS THEROF FOR ENHANCED GENOME EDITING | Centre For Oncology And Immunology Limited | GROOMS, TIFFANY NICOLE | §101§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 | |
| 18682594 | Pharmaceutical Compositions Comprising Dendritic Nanocarriers and Cannabis Active Agents | Dendropharm GmbH | CHI, AMANDA LYNN | 1613 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18681561 | FIBRINOGEN COMPOSITIONS AND METHODS OF PREPARATION | Biotest AG | GOTFREDSON, GAREN | 1619 | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18681271 | COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS | The University of Hong Kong | KAPUSHOC, STEPHEN THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18291999 | GENE SIGNATURE PREDICTING TERTIARY LYMPHOID STRUCTURES CONTAINING B CELLS | H. Lee Moffitt Cancer Center and Research Institute, Inc. | HAUK TEODORO, PRICILA NMN | 1645 | §101§103 | Final Rejection | — | Pending | Jan 25, 2024 |
| 18577631 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | BELL, SARA ELIZABETH | 1625 | §102§103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18542277 | DNA METHYLATION BIOMARKERS FOR CANCER DIAGNOSING | Arizona Board of Regents | GOLDBERG, JEANINE ANNE | 1682 | §102§112Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18538932 | SEQUENTIAL TRANSARTERIAL CHEMOEMBOLIZATION, STEREOTACTIC BODY RADIOTHERAPY, AND IMMUNOTHERAPY (START-FIT) FOR HEPATOCELLULAR CARCINOMA | The University of Hong Kong | MIDDLETON, DANAYA L | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18569361 | ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | The University of Hong Kong | CHANDRAKUMAR, NIZAL S | 1625 | §102§112Other | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18566491 | FIBROSIS BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE | The University of Hong Kong | SVEIVEN, MICHAEL CAMERON | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18565831 | METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS | Regents Of The University Of Minnesota | HAM, JIEUN | §103§112DP | Non-Final OA | — | Pending | Nov 30, 2023 | |
| 18565805 | CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER | H. Lee Moffitt Cancer Center and Research Institute, Inc. | LIU, SUE XU | §102§103§112Other | Non-Final OA | — | Pending | Nov 30, 2023 | |
| 18521615 | POLYMER COATED IRON OXIDE NANORODS AND METHODS OF MAKING AND USE THEREOF | 5M Biomed, LLC | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18563581 | IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY | H. Lee Moffitt Cancer Center and Research Institute, Inc. | AEDER, SEAN E | §112 | Final Rejection | — | Pending | Nov 22, 2023 | |
| 18563286 | THERMALLY ACTIVATED DELAYED FLUORESCENT PALLADIUM (II) COMPLEXES FOR OLED APPLICATIONS | Hong Kong Quantum AI Lab Limited | KOLLIAS, ALEXANDER C | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2023 | |
| 18506847 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS | BM Pharma Consulting Pty Ltd. | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18506988 | A-FABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF | Shenzhen Institute Of Advanced Technology, Chinese Academy Of Sciences | MCCOLLUM, ANDREA K | 1674 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18560347 | COMPOSITIONS AND METHODS OF TARGETING THE PAX6 SIGNALING PATHWAY TO REDUCE FORMATION OF AMYLOID BETA PLAQUES AND NEUROFIBRILLARY TANGLES | The University of Hong Kong | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18558943 | SEQUENCE-DEFINED POLYMERS WITH ONE OR MORE AZIDES, METHODS OF MAKING, AND METHODS OF USE THEREOF | Yale University | SPANGLER, JOSEPH RANKIN | 1656 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18490443 | USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING | The Regents of the University of California | PHILIPOSE, HANNAH SARAH | 1631 | §103§112 | Non-Final OA | 2d overdue | Pending | Oct 19, 2023 |
| 18554144 | EFFECT OF GHRH ANTAGONISTS IN DIABETES AND OBESITY | The United States Government AS Represented By The Dept. Of Veterans Affairs | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18375697 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | Ohio State Innovation Foundation | COUGHLIN, MATTHEW P | 1626 | §103 | Final Rejection | 29d overdue | Pending | Oct 02, 2023 |
| 18551025 | AN APPARATUS AND ASSOCIATED METHODS FOR THERMAL CYCLING | Bg Research Ltd. | YOUNG, NATASHA E | 3763 | §112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18466622 | METAL-ASSISTED MULTI-RESONANCE THERMALLY-ACTIVATED DELAYED-FLUORESCENCE EMITTERS FOR OLED APPLICATIONS | Hong Kong Quantum AI Lab Limited | NGUYEN, VU ANH | §102§112 | Non-Final OA | — | Pending | Sep 13, 2023 | |
| 18549950 | CHIPS AND METHODS | Imperial College Innovations Ltd. | KIDWELL, KAITLYN ELIZABETH | 2877 | §103 | Non-Final OA | 85d overdue | Pending | Sep 11, 2023 |
| 18464817 | Dental Care Products Comprising Stannous Flouride | Credentis AG | JAUHARI, SACHI | 1654 | §103 | Final Rejection | 26d | Pending | Sep 11, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.2% of resolved applications prosecuted by Pabst Patent Group, LLP were allowed, across 3,812 applications in USPTO records.
4.67 office actions per allowed application on average.
125 pending office actions as of October 2026, for 58 clients, before 115 examiners in 61 art units.